Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Japanese Subjects

• Status: Completed
• Trial end date: 2003-12-30
• Target enrollment: 0
• Participant gender: Male

Summary

This trial is conducted in Japan. The aim of this trial is to investigate the bioequivalence of two formulations of biphasic insulin aspart 50 (NN-X14Mix50) in healthy Japanese subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Biphasic Insulins; Insulin; Insulin Aspart; Insulin degludec, insulin aspart drug combination; Insulin, Long-Acting

Criteria

Inclusion Criteria:

• BMI (body mass index) between 19-29 kg/m^2 (both inclusive)

• Fasting blood glucose between 3.8-6.0 mmol/L (both inclusive)

• Non-smokers

Exclusion Criteria:

• Subjects with a first-degree relative with diabetes mellitus

• Subjects smoke 5 cigarettes or more per day